Study of BMS-587101 in Patients With Moderate to Severe Psoriasis

Stopped early · Phase 2

Conditions studied: Psoriasis, Moderate to Severe

In brief

The purpose of this clinical research study is to learn if BMS-587101 is effective on the treatment of Moderate to Severe Psoriasis. The safety of this treatment will also be studied.

Key facts

Study ID

NCT00162253

Run by

Bristol-Myers Squibb

People needed

120

Starts

2005-04-01

Last updated by the study team

2010-03-02

Who can join

Age: 18 and older, up to 75. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Local Institution — Phoenix, Arizona, United States
• Local Institution — Tucson, Arizona, United States
• Local Institution — San Diego, California, United States
• Local Institution — Miami Beach, Florida, United States
• Local Institution — Pinellas Park, Florida, United States
• Local Institution — Boise, Idaho, United States
• Local Institution — Fridley, Minnesota, United States
• Local Institution — St Louis, Missouri, United States
• Local Institution — New Brunswick, New Jersey, United States
• Local Institution — New York, New York, United States
• Local Institution — Winston-Salem, North Carolina, United States
• Local Institution — Columbus, Ohio, United States
• Local Institution — Portland, Oregon, United States
• Local Institution — Philadelphia, Pennsylvania, United States
• Local Institution — Greer, South Carolina, United States
• Local Institution — Dallas, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.